Table 2.
Clinical and Procedural Characteristics of patients.
| All patients n = 89 | Vaccinated n = 37 | Non-vaccinated n = 52 | P value | |
|---|---|---|---|---|
| STEMI | 56 (63) | 27 (73) | 29 (55.8) | 0.12 |
| NSTEMI | 23 (25.8) | 8 (21.6) | 15 (28.8) | 0.47 |
| UA | 10 (11.2) | 2 (5.4) | 8 (15.4) | 0.18 |
| Prior Thrombolysis | 8 (9) | 2 (5.4) | 6 (11.5) | 0.46 |
| Loading dose | ||||
| Aspirin | 89 (100) | 37 (100) | 52 (100) | 1.0 |
| Clopidogrel | 56 (62.9) | 22 (59.5) | 34 (65.4) | 0.66 |
| Ticagrelor | 23 (25.8) | 11 (29.7) | 12 (23.1) | 0.62 |
| Prasugrel | 4 (4.5) | 4 (10.8) | 0 | 0.03 |
| Culprit vessel: | ||||
| LAD | 49 (55.1) | 22 (59.5) | 27 (51.9) | 0.50 |
| RCA | 26 (29.2) | 10 (27.0) | 16 (30.8) | 0.77 |
| Cx | 14 (15.7) | 5 (13.5) | 9 (17.3) | 0.81 |
| Pre-PCI TIMI flow | 21, 2, 3 | 1 (0–3) | 21, 2, 3 | 0.03 |
| TIMI 0/1 flow | 43 (48.3) | 22 (59.5) | 21 (40.4) | 0.09 |
| Thrombus grade | 32, 3, 4 | 4 (2.5–5) | 21, 2, 3 | 0.0005 |
| PCI done | 65 (73) | 31 (83.8) | 34 (65.4) | 0.09 |
| Stent diameter | 2.75 (2.5–3) | 2.75 (2.5–3) | 3 (2.7–3) | 0.44 |
| Stent length | 26 (23–32.5) | 26 (23–33) | 26 (23–32) | 0.59 |
| Post PCI TIMI flow | 3 (3–3) | 3 (3–3) | 3 (3–3) | 0.62 |
| Gp2b3a inhibitor use | 10 (11.2) | 7 (18.9) | 3 (5.7) | 0.09 |
VG- Vaccinated group, NVG- Non-Vaccinated group, LAD- Left anterior descending artery, RCA- Right coronary artery, Cx- Circumflex artery, PCI – Percutaneous coronary intervention, TIMI- Thrombolysis in myocardial infarction, GP2b3a- Glycoprotein 2b3a.